Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
Yamamoto Y., Taniguchi T., Inazumi T., Iwamura R., Yoneda K., Odani-Kawabata N., Matsugi T., Sugimoto Y., Shams N.K.
View publication
-
Therapeutic Area
Glaucoma
-
Categories
Preclinical development
-
Affiliations
Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Research and Development Division, Santen, Inc., Emeryville, CA, United States